Editor in Chief's Invitation to Contribute

Dear colleagues,

I would like to invite you to submit a paper to Drug Target Insights – one of the most successful journals published by Libertas Academica, with a view factor of more than 70,000.

Drug Target Insights welcomes manuscripts reporting original and unpublished research regarding any aspect of the field of clinical therapeutics. More specifically, topics can range from the description molecular drug targets to the patients’ perspective on a particular therapeutic treatment. There is no restriction on the pathology under study.

All papers will be refereed within a peer-review system. Reviewers are experts in the field and will provide comments in a timely manner. Your paper will be indexed by the following databases: Embase, Google scholar, CAS, and DOAJ. Most importantly, in the event that your research is NIH funded, your paper will be also added to the Pubmed database.

Getting your paper published in an open access journal, such as Drug Target Insights, will benefit both you and the scientific community. You will benefit by making your research visible to the widest possible scientific audience. The scientific community will benefit from the fact that anyone will be able to learn about the latest discoveries in the field at no cost. When information is available to everybody, progress proceeds at the fastest pace.

Advantages of Publishing

• Visibility: high on-website open access visibility and indexing in Chemical Abstracts Service, Directory of Open Access Journals, EBSCO Academic Search Complete, EMBase, Google Scholar, OAlster, Open J-Gate, Socolar

• Speed: just 21 days average to first editorial decision including two high-quality peer reviews

• Service: accessible professional staff

• Author rewards: submit more than one paper over 365 days and high-priority processing and production and progressively higher levels of article processing fee discount

What Do Your Colleagues Say?

"My experience with Libertas Academica was excellent. The review process was smooth and speedy. After publishing, I received a kind and favorable response from a reader. I have never experienced such a comment after my publications to orthodox journals." -Dr Hiro Koshiyama.  More testimonials...

Read more about preparing your manuscript for submission and watch a video on how to submit it.

Yours sincerely,

Dr Monica Milani
Editor-in-Chief
Drug Target Insights